US FDA lowers risk classification for cardiac allograft gene expression profiling tests
This article was originally published in RAJ Devices
The US Food and Drug Administration has classified cardiac allograft gene expression profiling test systems as medium-risk (Class II) devices1 and established special controls that would provide a reasonable assurance of safety and effectiveness of such products2,3.
You may also be interested in...
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.
A damning UK report makes uncomfortable reading about how thousands of women suffered avoidable harm from the anti-epileptic drug sodium valproate and two other medical interventions and how safety concerns raised were dismissed, overlooked and ignored.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.